By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cerecor Inc. 

2400 Boston Street, Suite 324

Baltimore  Maryland  21224  U.S.A.
Phone: 410-522-8707 Fax: n/a


Start Up

Company News
Cerecor Inc. Announces Acquisition Of TARP-G8-AMPA Receptor Antagonist (CERC-611) From Eli Lilly (LLY) 9/26/2016 11:01:46 AM
Cerecor Inc. Announces Completion Of Enrollment In Phase II Clinical Trial With CERC-301 As An Oral, Adjunctive Treatment Of Major Depressive Disorder 9/21/2016 11:08:42 AM
Cerecor Inc. Enters Into A $15 Million Common Stock Purchase Agreement With Aspire Capital Fund 9/12/2016 10:27:22 AM
Cerecor Inc. Announces Last Patient Enrolled In Phase II Clinical Trial With CERC-501 For Smoking Cessation 9/6/2016 11:02:20 AM
Cerecor Inc. To Present At 23rd Annual Newsmakers In The Biotech Industry Conference In New York City, September 9, 2016 9/1/2016 10:45:12 AM
Cerecor Inc. Announces Initiation Of Second CERC-501 Phase II Clinical Trial In Smokers 8/29/2016 8:22:55 AM
Cerecor Inc. To Present At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13th, 2016 8/22/2016 10:27:23 AM
Cerecor Inc. Reports Second Quarter 2016 Financial Results 8/15/2016 12:31:09 PM
Cerecor Inc. Announces Research Grant From The Department Of Defense To Study CERC-501 In Animal Models For Co-Morbid Post-Traumatic Stress Disorder And Alcohol Use Disorder 7/25/2016 10:53:57 AM
Cerecor Inc. Announces $1 Million Research & Development Grant From The National Institute On Alcohol Abuse And Alcoholism At The NIH 7/20/2016 11:00:19 AM